Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

Oncologist

Volumn 14, Issue 5, 2009, Pages 478-488

  Köhne, Claus Henning ^a   Lenz, Heinz Josef ^b  

^a KLINIKUM OLDENBURG   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Irinotecan; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANTINEOPLASTIC ACTIVITY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAIR GROWTH; HAIR LOSS; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INJECTION SITE REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOSE SEPTUM PERFORATION; ONCOGENE K RAS; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREMEDICATION; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SKIN PRURITUS; SKIN TOXICITY; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; WOUND COMPLICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PHTHALAZINES; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66349093145     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0202     Document Type: Review

References (76)

1. World Health Organization. Cancer. Key Facts. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html, accessed June 4, 2008.
2. Garcia M, Jemal A, Ward EM et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007:1-50.
3. Van Cutsem E, Geboes K. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol 2007;21:1089-1108. (Pubitemid 350218037)
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
5. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004;22:3766-3775.
6. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 1997;15:808-815. (Pubitemid 27074252)
7. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308. (Pubitemid 28041613)
8. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003;21:2896-2903. (Pubitemid 46621839)
9. Folprecht G, Lutz MP, Schöffski P et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-456. (Pubitemid 43329582)
10. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. The Oncologist 2005;10(suppl 3):40-48. (Pubitemid 43152729)
11. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The Oncologist 2007;12:38-50. (Pubitemid 46143501)
12. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008;26:1774-1777.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
14. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027. (Pubitemid 46202320)
15. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
16. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. (Pubitemid 38944402)
17. Messa C, Russo F, Caruso MG et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285-289.
18. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-115. (Pubitemid 30114656)
19. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970. (Pubitemid 32963812)
20. Ponz-Sarvisé M, Rodríguez J, Viudez A et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new? World J Gastroenterol 2007;13:5877-5887. (Pubitemid 350148504)
21. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799. (Pubitemid 46606324)
22. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844. (Pubitemid 23132159)
23. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
24. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712. (Pubitemid 46252465)
25. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705. (Pubitemid 46252464)
26. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
27. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508. (Pubitemid 46243494)
28. Avastin prescribing information. Available at http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf, accessed July 20, 2006.
29. Fuchs CS, Marshal J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007;25:4779-4786. (Pubitemid 350086481)
30. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008;26:689-690.
31. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
32. Köhne CH, De Greve J, Hartmann JT et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-926.
33. Ziras N, Polyzos A, Kakolyris S et al. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial. J Clin Oncol 2008;26(suppl 20):15008.
34. Grothey A, Sugrue M, Hedrick E et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). J Clin Oncol 2007;25(suppl 18):4036.
35. Prewett MC, Hooper AT, Bassi R et al. Enhanced antitumor activity of antiepidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003. (Pubitemid 34517632)
36. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208. (Pubitemid 41079832)
37. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048. (Pubitemid 350106711)
38. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
39. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25(suppl 18):4000.
40. Ciuleanu TE, Kurteva G, Ocvirk J et al. A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2008;26(suppl 20):4032.
41. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the German AIO CRC study group. J Clin Oncol 2008;26(suppl 20):4033.
42. Smedra F, Viret Y, Toiron Y et al. Serum proteomic prediction of progression-free survival in cetuximab-treated metastatic colorectal cancer patients. Presented at the 2008 Gastrointestinal Cancers Symposium of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
43. Vincenzi B, Santini D, Funaioli C et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab + irinotecan as predictive factor of efficacy and outcome. J Clin Oncol 2008;26(suppl 20):4106.
44. Scartozzi M, Bearzi I, Pierantoni C et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) detected by chromogenic in situ hybridization (CISH) correlates with clinical activity of irinotecan-cetuximab in colorectal cancer. Presented at the 2008 Gastrointestinal Cancers Symposium of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
45. Graziano F, Ruzzo A, Loupakis F et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427-1434.
46. Jhawer M, Goel S, Wilson AJ et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68:1953-1961.
47. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
48. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
49. Di Fiore F, Van Cutsem E, Laurent-Puig P et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. J Clin Oncol 2008;26(suppl 20):4035.
50. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008;26(suppl 20):4000.
51. Cervantes T, Macarulla E, Martinelli E et al. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2008;26(suppl 20):4129.
52. Tejpar S, Peeters M, Humblet Y et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 2008;26(suppl 20):4001.
53. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008;26(suppl 20):2.
54. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Presented at the 2008 Gastrointestinal Cancers Symposium of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
55. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664. (Pubitemid 46797944)
56. AMGEN news release. KRAS gene status may impact Vectibix™ (panitumumab) efficacy and patient reported outcomes in advanced colorectal cancer patients. Available at http://wwwext.amgen.com/media/media-pr-detail.jsp? year=2008&releaseID=1099452, accessed January 24, 2008.
57. Saltz LB, Lenz HJ, Kindler HL et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007;25:4557-4561. (Pubitemid 350035312)
58. Punt CJ, Tol J, Rodenburg CJ et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008;26(suppl 20):LBA4011.
59. Punt CJ, Tol J, Rodenburg CJ et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Presented at the 2008 Gastrointestinal Cancers Symposium of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
60. Hecht JR, Mitchell E, Chidiac T et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at the 2008 Gastrointestinal Cancers Symposium of 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
61. Hecht JR, Mitchell E, Chidiac T et al. Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). Presented at the 2008 Gastrointestinal Cancers Symposium of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30 to June 3, 2008.
62. Peeters M, Wilson G, Hotko Y et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. J Clin Oncol 2008;26(suppl 20):4064.
63. Skillings JR, Johnson DH, Miller K et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23(suppl 16):3019.
64. Kesmodel SB, Ellis LM, Lin E et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. Presented at the 2007 Gastrointestinal Cancers Symposium of the 43rd Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, January 17-21, 2007.
65. Bevacizumab: Serious neurological disorders and nasal perforations. Prescrire Int 2007;16:112. (Pubitemid 47249651)
66. Berry SR, Van Cutsem E, Kretzschmar A et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 2008;26(suppl 20):4025.
67. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812. (Pubitemid 44450468)
68. Saltz LB, Kies M, Abbruzzese J et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 to June 3, 2003.
69. Eng C, Maurel J, Scheithauer W et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 2007;25(suppl 18):4003.
70. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. The Oncologist 2007;12:610-621. (Pubitemid 350012125)
71. Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006;20(suppl 2):35-40.
72. Thomas AL, Trarbach T, Bartel C et al. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 2007;18:782-788. (Pubitemid 46523285)
73. Trarbach T, Schleucher N, Tewes M et al. Phase I/II study of PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
74. Hecht J, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK 787/ZK 222584 or placebo (CONFIRM-1). Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
75. Lenz HW, Zhang W, Shi MM et al. ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2. J Clin Oncol 2008;26(suppl 20):4131.
76. Wilson PM, Yang D, Shi MM et al. Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2. J Clin Oncol 2008;26(suppl 20):4002.